Laukkanen Mikko O, Castellone Maria Domenica
Istituto di Endocrinologia ed Oncologia Sperimentale "G. Salvatore" (IEOS), C.N.R. Via S. Pansini, 5, 80131- Naples; Italy.
Anticancer Agents Med Chem. 2016;16(3):309-17. doi: 10.2174/1871520615666151007160439.
The hedgehog (Hh) signaling pathway, which is almost completely silenced in normal adult tissues but highly activated in cancer, offers ideal drug targets for small molecule development. During the last few years, several studies have indicated that the Hh pathway plays a role in tumor development and maintenance, and novel drugs inhibiting Hh signaling have been discovered. Although results from clinical trials in patients harboring activating mutations of Hh have been promising, there are many controversies regarding the role of the pathway in tumors that demonstrate ligand over-expression without identified mutations. In this review, we focus on the function and expression of the Hh pathway in different tumors and discuss the targeting approaches tested in preclinical and clinical studies.
刺猬索尼克(Hh)信号通路在正常成人组织中几乎完全沉默,但在癌症中高度激活,为小分子药物开发提供了理想的靶点。在过去几年中,多项研究表明Hh通路在肿瘤发生和维持中发挥作用,并且已经发现了抑制Hh信号的新型药物。尽管在携带Hh激活突变的患者中进行的临床试验结果很有前景,但关于该通路在未发现突变但有配体过表达的肿瘤中的作用仍存在许多争议。在这篇综述中,我们重点关注Hh通路在不同肿瘤中的功能和表达,并讨论在临床前和临床研究中测试的靶向方法。